BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 3095635)

  • 21. YAC-1 MHC class I variants reveal an association between decreased NK sensitivity and increased H-2 expression after interferon treatment or in vivo passage.
    Piontek GE; Taniguchi K; Ljunggren HG; Grönberg A; Kiessling R; Klein G; Kärre K
    J Immunol; 1985 Dec; 135(6):4281-8. PubMed ID: 3905967
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antileukemia activity of a natural killer cell line against human leukemias.
    Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
    Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differences in target cell DNA fragmentation induced by mouse cytotoxic T lymphocytes and natural killer cells.
    Duke RC; Cohen JJ; Chervenak R
    J Immunol; 1986 Sep; 137(5):1442-7. PubMed ID: 2943792
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Susceptibility to natural killer cell-mediated cytolysis is independent of the level of target cell class I HLA expression.
    Leiden JM; Karpinski BA; Gottschalk L; Kornbluth J
    J Immunol; 1989 Mar; 142(6):2140-7. PubMed ID: 2493507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of a murine lymphoma model system for the characterization of natural killer:tumor cell interactions.
    Smithson G; Wolcott RM; Chervenak R
    Cancer Res; 1992 Aug; 52(15):4149-56. PubMed ID: 1638530
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Properties and characterization of a rat spleen cell-derived factor that induces resistance to natural killer cell lysis in YAC lymphoma cells.
    Saxena RK; Saxena QB; Adler WH
    J Immunol; 1988 Sep; 141(5):1782-7. PubMed ID: 2457628
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of altered membrane structure on NK cell-mediated cytotoxicity. II. Conversion of NK-resistant tumor cells into NK-sensitive targets upon fusion with liposomes containing NK-sensitive membranes.
    Roozemond RC; van der Geer P; Bonavida B
    J Immunol; 1986 May; 136(10):3921-9. PubMed ID: 3701064
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IL-10 converts mouse lymphoma cells to a CTL-resistant, NK-sensitive phenotype with low but peptide-inducible MHC class I expression.
    Salazar-Onfray F; Petersson M; Franksson L; Matsuda M; Blankenstein T; Kärre K; Kiessling R
    J Immunol; 1995 Jun; 154(12):6291-8. PubMed ID: 7759867
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of rat natural killer cytotoxic factor (NKCF) produced by rat NK cell lines and the production of a murine monoclonal antibody that neutralizes NKCF.
    Ortaldo JR; Winkler-Pickett R; Morgan AC; Woodhouse C; Kantor R; Reynolds CW
    J Immunol; 1987 Nov; 139(9):3159-65. PubMed ID: 3668253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanism of cell-mediated cytotoxicity at the single cell level. VI. Direct assessment of the cytotoxic potential of human peripheral blood non-lytic effector-target cell conjugates.
    Bonavida B; Lebow LT; Bradley TP
    J Immunol; 1984 Feb; 132(2):594-8. PubMed ID: 6606675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lysis of human cytomegalovirus infected fibroblasts by natural killer cells: demonstration of an interferon-independent component requiring expression of early viral proteins and characterization of effector cells.
    Borysiewicz LK; Rodgers B; Morris S; Graham S; Sissons JG
    J Immunol; 1985 Apr; 134(4):2695-701. PubMed ID: 2579152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Studies on the mechanism of natural killer cytotoxicity. III. Activation of NK cells by interferon augments the lytic activity of released natural killer cytotoxic factors (NKCF).
    Wright SC; Bonavida B
    J Immunol; 1983 Jun; 130(6):2960-4. PubMed ID: 6189908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human oncogene-transfected tumor cells display differential susceptibility to lysis by lymphokine-activated killer cells (LAK) and natural killer cells.
    Lanza LA; Wilson DJ; Ikejiri B; Roth JA; Grimm EA
    J Immunol; 1986 Oct; 137(8):2716-20. PubMed ID: 3489774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term killing of natural killer-resistant target cells by interferon-alpha-, interferon-gamma-, and interleukin-2-activated natural killer cells.
    Sarzotti M; Klimpel GR; Baron S
    Nat Immun Cell Growth Regul; 1989; 8(2):66-75. PubMed ID: 2503715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of altered membrane fluidity on NK cell-mediated cytotoxicity. I. Selective inhibition of the recognition or post recognition events in the cytolytic pathway of NK cells.
    Roozemond RC; Bonavida B
    J Immunol; 1985 Apr; 134(4):2209-14. PubMed ID: 3855929
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Studies on the mechanism of natural killer cell-mediated cytotoxicity. VII. functional comparison of human natural killer cytotoxic factors with recombinant lymphotoxin and tumor necrosis factor.
    Wright SC; Bonavida B
    J Immunol; 1987 Mar; 138(6):1791-8. PubMed ID: 3493288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Purification and target cell range of in vivo elicited blast natural killer cells.
    Biron CA; Pedersen KF; Welsh RM
    J Immunol; 1986 Jul; 137(2):463-71. PubMed ID: 3722814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced lytic susceptibility of Ha-ras transformants after oncogene induction is specific to activated NK cells.
    Johnson PW; Trimble WS; Hozumi N; Roder JC
    J Immunol; 1987 Jun; 138(11):3996-4003. PubMed ID: 3495578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of cloned cytotoxic lymphocytes with NK-like activity.
    Acha-Orbea H; Groscurth P; Lang R; Stitz L; Hengartner H
    J Immunol; 1983 Jun; 130(6):2952-9. PubMed ID: 6189907
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor necrosis factor-alpha enhances cytolytic activity of human natural killer cells.
    Ostensen ME; Thiele DL; Lipsky PE
    J Immunol; 1987 Jun; 138(12):4185-91. PubMed ID: 3108384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.